Hepion Pharmaceuticals, Inc. (HEPA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Hepion Pharmaceuticals, Inc. (HEPA) is up 5.0% since the beginning of the year. At $0 per share, HEPA is trading 74.8% below its 52-week high of $0. Investors who bought $1,000 worth of HEPA shares 5 years ago would now be looking at an investment worth $0.

Hepion Pharmaceuticals, Inc. (HEPA) has returned 5.00% so far this year and 56.72% over the past 12 months. Over the last ten years, HEPA has returned -79.87% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Feb 11, 2014, HEPA's average daily return is -0.17%, while the average monthly return is -4.89%.

Historically, 34% of months were positive and 66% were negative. The best month was Jan 2023 with a return of +143.0%, while the worst month was Mar 2025 at -93.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.

On a daily basis, HEPA closed higher 41% of trading days. The best single day was Oct 5, 2015 with a return of +123.7%, while the worst single day was Jan 22, 2025 at -58.1%.

Hepion Pharmaceuticals, Inc. has an annualized alpha of -40.76%, beta of 0.76, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since February 12, 2014.

• This stock participated in 248.10% of S&P 500 Index downside but only -132.16% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

HEPA ranks 64 for risk / return — better than 64% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Hepion Pharmaceuticals, Inc. (HEPA) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Hepion Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Hepion Pharmaceuticals, Inc. was 100.00%, occurring on Jan 30, 2026. The portfolio has not yet recovered.

The current Hepion Pharmaceuticals, Inc. drawdown is 100.00%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Hepion Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Hepion Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.